Plain-English translation of NCT06718738 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called IM96 CAR-T cell therapy for people with advanced colorectal cancer that has not responded to or become too difficult to tolerate with standard chemotherapy. The treatment works by taking your own immune cells, modifying them in a laboratory to better recognize and attack cancer cells, and then putting them back into your body. This is a Phase 1 trial, which means researchers are still learning about the treatment's safety and how well it works.
Standard chemotherapy treatments for advanced colorectal cancer don't work for everyone, and some patients cannot tolerate the side effects. This medication represents a new approach using your own immune system to fight the cancer, which may help patients who have run out of other options.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You would undergo several phases: first, screening tests to confirm you qualify; then blood collection to harvest your immune cells; chemotherapy pretreatment to prepare your body; and finally, infusion of the modified immune cells back into your bloodstream. Researchers will closely monitor you for the first 28 days after infusion to watch for any side effects and to see how your body responds. You'll have follow-up visits and tests to track your health over time.
AI-generated summary from trial data ยท Jul 3, 2026 ยท Not medical advice
China
Phase
Safety & dosing
Sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd.
Collaborators
Peking University Cancer Hospital & Institute
Enrollment target
~9 participants
Started
December 2024
Primary completion
August 2025
This trial's estimated completion date has passed โ the record may not be fully up to date.
Age range
18 Years โ 75 Years
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Fei Wu
Peking University Cancer Hospital & Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.